Intelligent Bio Solutions (INBS) investor relations material

Business overview

• Delivers rapid, non-invasive drug testing solutions using fingerprint sweat analysis, targeting improved accessibility and quality of life.

• Focuses on pain-free, cost-effective, and reliable testing for workplace drugs such as opiates, cocaine, methamphetamine, and cannabis.

• Employs a consumables-led recurring revenue model with growing cartridge sales and installed readers.

• Holds a strong IP portfolio with multiple patents granted in the U.S. and Europe.

Product features and benefits

• Three-step testing process delivers results in under 10 minutes, with ongoing validation for even faster results.

• Detects recent drug use within 16–24 hours, focusing on current impairment rather than historical use.

• Portable, hygienic, and administrator-supervised system preserves dignity and ensures sample integrity.

• Offers up to 99% accuracy and lower annual costs compared to urine and saliva testing.

Market opportunity and customer base

• Addresses a $400 billion global substance abuse problem, with the drug screening market projected to reach $31 billion by 2032.

• U.S. market valued at $4.6 billion in 2025, expected to double by 2030, driven by regulatory and workplace safety needs.

• Over 500 active customer accounts across 35 countries, with 1,800+ installed readers.

• Target sectors include government, law enforcement, healthcare, sports, aviation, and energy.